Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
The latest news, research, and perspectives in myeloproliferative neoplasms (MPNs). MPNs occur when the bone marrow produces too many red blood cells, platelets, or certain white blood cells. The primary subtypes include myelofibrosis, polycythemia vera, and essential thrombocythemia.
Advertisement
Melissa BadamoMyelofibrosis | November 4, 2024
Pacritinib demonstrated superiority to best available therapy for spleen volume reduction, total symptom score, and more.
Melissa BadamoMyelofibrosis | November 13, 2024
Patients with splenomegaly are more likely to be referred for HSCT.
Melissa BadamoMyelofibrosis | November 4, 2024
Selinexor plus ruxolitinib was well tolerated, reduced symptom burden, and led to spleen volume reduction.
Melissa BadamoMyelofibrosis | November 4, 2024
One year of pacritinib treatment stabilized or improved thrombocytopenia and anemia in patients with myelofibrosis.
Cailin ConnerMyelofibrosis | October 8, 2024
The phase III PERSIST-2 study compared symptom results from pacritinib with those of best available therapy and ruxolitinib.
Cailin ConnerMyelofibrosis | October 8, 2024
Patients' genomic profiles and baseline laboratory values have implications for their treatment outcomes with these agents.
Advertisement
Cailin ConnerMyelofibrosis | October 8, 2024
The International Prognostic Scoring System, Dynamic International Prognostic Scoring System, and other models were applied.
Cailin ConnerMyelofibrosis | October 9, 2024
A retrospective study found momelotinib plus pacritinib led to reduced need for red blood cell transfusion in patients.
Andrew MorenoMyelofibrosis | September 30, 2024
A real-world retrospective study evaluated transfusion dependent or nondependent patients at ruxolitinib initiation.
Andrew MorenoMyelofibrosis | September 27, 2024
Management of asymptomatic, clinically stable disease is not necessarily improved by implementing routine hemostasis tests.
Andrew MorenoMyelofibrosis | September 27, 2024
Investigational agent DISC-0974 produced anemia response independent of patient transfusion dependency or JAK inhibitor use.
Andrew MorenoMyelofibrosis | September 26, 2024
A study observed that addition of pelabresib to ruxolitinib led to bone marrow microenvironment improvement.
Prithviraj Bose, MDMyelofibrosis | September 25, 2024
An expert on myelofibrosis comments on promising results from current trials and on the need for useful clinical biomarkers.
Melissa BadamoMyelofibrosis | September 13, 2024
History of thrombotic events, hematocrit ≤0.45 L/L, and JAK2 p.V617F were identified as risk factors for progression.
Melissa BadamoMyelofibrosis | September 13, 2024
LOXL2 upregulation is associated with key inflammatory signaling pathways in primary myelofibrosis.
Melissa BadamoMyelofibrosis | September 13, 2024
Treatment with selinexor reduced hepcidin and pro-inflammatory cytokines in patients with myelofibrosis.
Melissa BadamoMyelofibrosis | September 13, 2024
The rates of baseline comorbidities and constitutional symptoms were higher in patients with anemia versus those without.
Rob DillardMyelofibrosis | September 10, 2024
New or worsening anemia following initiation of ruxolitinib does not appear to diminish clinical benefit.
Rob DillardMyelofibrosis | September 10, 2024
Hemoglobin improvement at week 24 after transfusion is associated with improved HRQOL in myelofibrosis and anemia.
Rob DillardMyelofibrosis | September 10, 2024
Prospective analysis suggest that 4.3% of patients with ET progressed to myelofibrosis over five years of follow up.
Advertisement
Advertisement
Editorial Board